XML 109 R11.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Revenues | 12 Months Ended
--- | ---
Dec. 31, 2019
Revenue from Contract with Customer [Abstract] |
Revenues | Revenues We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. Rest-of-world (ROW) revenues relate to products that are sold primarily in Europe. Revenues were as follows (in millions):
|  | Year ended December 31, 2019
|  | U.S. |  | ROW |  | Total
Enbrel® (etanercept) |  | $ | 5,050 |  |  | $ | 176 |  |  | $ | 5,226 |
Neulasta® (pegfilgrastim) |  | 2,814 |  |  | 407 |  |  | 3,221 |
Prolia® (denosumab) |  | 1,772 |  |  | 900 |  |  | 2,672 |
XGEVA® (denosumab) |  | 1,457 |  |  | 478 |  |  | 1,935 |
Aranesp® (darbepoetin alfa) |  | 758 |  |  | 971 |  |  | 1,729 |
KYPROLIS® (carfilzomib) |  | 654 |  |  | 390 |  |  | 1,044 |
EPOGEN® (epoetin alfa) |  | 867 |  |  | — |  |  | 867 |
Sensipar®/Mimpara® (cinacalcet) |  | 252 |  |  | 299 |  |  | 551 |
Other products |  | 2,907 |  |  | 2,052 |  |  | 4,959 |
Total product sales(1) |  | 16,531 |  |  | 5,673 |  |  | 22,204 |
Other revenues |  | 693 |  |  | 465 |  |  | 1,158 |
Total revenues |  | $ | 17,224 |  |  | $ | 6,138 |  |  | $ | 23,362 |
|  | Year ended December 31, 2018
|  | U.S. |  | ROW |  | Total
ENBREL |  | $ | 4,807 |  |  | $ | 207 |  |  | $ | 5,014 |
Neulasta® |  | 3,866 |  |  | 609 |  |  | 4,475 |
Prolia® |  | 1,500 |  |  | 791 |  |  | 2,291 |
Aranesp® |  | 942 |  |  | 935 |  |  | 1,877 |
XGEVA® |  | 1,338 |  |  | 448 |  |  | 1,786 |
Sensipar®/Mimpara® |  | 1,436 |  |  | 338 |  |  | 1,774 |
EPOGEN® |  | 1,010 |  |  | — |  |  | 1,010 |
KYPROLIS® |  | 583 |  |  | 385 |  |  | 968 |
Other products |  | 1,947 |  |  | 1,391 |  |  | 3,338 |
Total product sales(1) |  | 17,429 |  |  | 5,104 |  |  | 22,533 |
Other revenues |  | 929 |  |  | 285 |  |  | 1,214 |
Total revenues |  | $ | 18,358 |  |  | $ | 5,389 |  |  | $ | 23,747 |
|  | Year ended December 31, 2017
|  | U.S. |  | ROW |  | Total
ENBREL |  | $ | 5,206 |  |  | $ | 227 |  |  | $ | 5,433 |
Neulasta® |  | 3,931 |  |  | 603 |  |  | 4,534 |
Aranesp® |  | 1,114 |  |  | 939 |  |  | 2,053 |
Prolia® |  | 1,272 |  |  | 696 |  |  | 1,968 |
Sensipar®/Mimpara® |  | 1,374 |  |  | 344 |  |  | 1,718 |
XGEVA® |  | 1,157 |  |  | 418 |  |  | 1,575 |
EPOGEN® |  | 1,096 |  |  | — |  |  | 1,096 |
KYPROLIS® |  | 562 |  |  | 273 |  |  | 835 |
Other products |  | 1,419 |  |  | 1,164 |  |  | 2,583 |
Total product sales(1) |  | 17,131 |  |  | 4,664 |  |  | 21,795 |
Other revenues |  | 898 |  |  | 156 |  |  | 1,054 |
Total revenues |  | $ | 18,029 |  |  | $ | 4,820 |  |  | $ | 22,849 |
____________
(1) | Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2019, 2018 and 2017.
In the United States, we sell primarily to pharmaceutical wholesale distributors that we utilize as the principal means of distributing our products to healthcare providers. Outside the United States, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers and limit our credit exposure by setting credit limits and, in certain circumstances, by requiring letters of credit or obtaining credit insurance. We had product sales to three customers, each of them accounting for more than 10% of total revenues for each of the years ended December 31, 2019, 2018 and 2017. For the year ended December 31, 2019, on a combined basis, these customers accounted for 81% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions):
| Years ended December 31,
| 2019 |  | 2018 |  | 2017
AmerisourceBergen Corporation: |  |  |  |  |
Gross product sales | $ | 12,301 |  |  | $ | 12,091 |  |  | $ | 10,742 |
% of total gross revenues | 33 | % |  | 33 | % |  | 31 | %
McKesson Corporation: |  |  |  |  |
Gross product sales | $ | 11,795 |  |  | $ | 11,434 |  |  | 10,625 |
% of total gross revenues | 31 | % |  | 31 | % |  | 30 | %
Cardinal Health, Inc.: |  |  |  |  |
Gross product sales | $ | 6,538 |  |  | $ | 7,475 |  |  | $ | 7,049 |
% of total gross revenues | 17 | % |  | 20 | % |  | 20 | %
As of December 31, 2019 and 2018, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 73% and 76%, respectively, of net trade receivables on a combined basis. As of December 31, 2019 and 2018, 27% and 23%, respectively, of trade receivables, net, were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2019 and 2018 was not material.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration